Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Change in Account Payables (2016 - 2025)

Lipocine (LPCN) has disclosed Change in Account Payables for 13 consecutive years, with $418458.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables rose 356.01% year-over-year to $418458.0, compared with a TTM value of $576105.0 through Sep 2025, up 170.63%, and an annual FY2024 reading of -$1.1 million, down 241.31% over the prior year.
  • Change in Account Payables was $418458.0 for Q3 2025 at Lipocine, up from $82755.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $583481.0 in Q3 2023 and bottomed at -$1.0 million in Q1 2021.
  • Average Change in Account Payables over 5 years is -$38724.6, with a median of -$13651.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables soared 1080.81% in 2023, then plummeted 469.49% in 2024.
  • Year by year, Change in Account Payables stood at $563790.0 in 2021, then crashed by 105.33% to -$30068.0 in 2022, then skyrocketed by 1080.81% to $294909.0 in 2023, then tumbled by 104.63% to -$13651.0 in 2024, then skyrocketed by 3165.4% to $418458.0 in 2025.
  • Business Quant data shows Change in Account Payables for LPCN at $418458.0 in Q3 2025, $82755.0 in Q2 2025, and $88543.0 in Q1 2025.